Advertisement
Codexis Inks Purchase Deal With Nestle Health Science For CDX-7108
(RTTNews) - Enzyme engineering company Codexis, Inc. (CDXS) announced Wednesday it has entered into a purchase agreement with Nestle Health Science for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI).
Under the terms of the agreement, Codexis will receive up to $45 million in potential milestone payments, including a $5 million upfront payment, as well as single-digit net-sales-based royalties.
Codexis will receive up to an additional $5 million if Nestle Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI.
Nestle Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs.
Codexis and Nestle Health Science completed pre-clinical work for CDX-7108 and a Phase I clinical trial under the terms of a previous agreement. With this asset purchase agreement, Nestle Health Science may continue advancing the compound through the development process.
Eurozone Retail Sales Recover In June
Euro Rises As European Shares Traded Higher
Disney Lifts FY25 EPS View After Q3 Profit Beats Market; ESPN In Deal With WWE, NFL
Dynatrace Boosts FY26 Outlook - Update
FTSE 100 Modestly Higher; Hiscox Soars 9%
CAC 40 Up In Positive Territory In Cautious Trade
Euro Rises Against Majors
